The following government grants in the FederalGrants.com database contain the term housing in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| Cooperative Centers on Human Immunology (U19 Clinical Trial Optional) |
93.855 |
RFA-AI-22-069 |
| HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional) |
93.273, 93.279 |
RFA-DA-23-060 |
| HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional) |
93.213, 93.273, 93.279 |
RFA-DA-23-059 |
| Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed) |
93.077 |
RFA-OD-22-023 |
| Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required ) |
93.077 |
RFA-OD-22-026 |
| Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required) |
93.077 |
RFA-OD-22-024 |
| Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed) |
93.077 |
RFA-OD-22-025 |
| HUD FY2022 Healthy Homes and Weatherization Cooperation Demonstration |
14.901 |
FR-6600-N-62 |
| Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) |
93.173, 93.242, 93.273, 93.866, 93.867 |
PAR-23-047 |
| Affordable Connectivity Outreach Grant Program |
32.011 |
FCC-ACOGP-23-001 |
| Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed) |
93.173, 93.242, 93.273, 93.866, 93.867 |
PAR-23-046 |
| Transformative Educational Advancement and Mentoring Network (TEAM) (R25 Clinical Trial Not Allowed) |
93.398 |
RFA-CA-23-013 |
| Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) |
93.279 |
RFA-DA-23-036 |
| F23AS00069 Youth Engagement, Education, and Employment |
15.676 |
F23AS00069 |
| HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain(RM1 Clinical Trial Optional) |
93.121, 93.233, 93.273, 93.393, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.853, 93.865, 93.866 |
RFA-NS-22-069 |
| Fiscal Year (FY) 2023 AmeriCorps Seniors Workforce Development |
94.017 |
AC-11-04-22 |
| Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed) |
93.279 |
RFA-DA-24-004 |
| Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) |
93.279 |
RFA-DA-24-003 |
| Pediatric Critical Care and Trauma Scientist Development Program (K12 Clinical Trial Optional) |
93.865 |
RFA-HD-24-001 |
| Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) |
93.855 |
PAR-23-033 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed) |
93.394 |
RFA-CA-23-019 |
| U.S. Embassy Apia, Samoa -- PDS Annual Program Statement |
19.040 |
PDS-SAMOA-2023-01 |
| Funding Opportunity Department of Veteran Affairs Supportive Services for Veteran Families |
64.033 |
VASSVF2024 |
| Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) |
93.279 |
PAR-23-041 |
| Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement Clinical Trial Optional) |
93.866 |
PA-23-044 |
| FY22 HOPE VI Main Street Grant Program |
14.878 |
FR-6600-N-03 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed) |
93.394, 93.396 |
RFA-CA-23-018 |
| Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic (PBPK) Modeling (U01) Clinical Trial Optional |
93.103 |
RFA-FD-23-015 |
| Evaluation of oral modified release drug tablet to support the approval of additional strengths |
93.103 |
RFA-FD-23-013 |
| Population Pharmacokinetic Modeling of Systemic Pharmacokinetic Data to Inform Bioequivalence in Regional Lung Exposure (U01) Clinical Trial Not Allowed |
93.103 |
RFA-FD-23-017 |
| In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required |
93.103 |
RFA-FD-23-014 |
| Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed |
93.103 |
RFA-FD-23-012 |
| Designing and performing a virtual bioequivalence trial for physiologically-based pharmacokinetic and other mechanism-based models |
93.103 |
RFA-FD-23-016 |
| Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01) |
93.351 |
PAR-23-040 |
| Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) |
93.242 |
PAR-22-252 |
| HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed) |
93.242, 93.855 |
PAR-22-248 |
| Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R24 Clinical Trials Not Allowed) |
93.351 |
PAR-23-039 |
| U.S. Mission New Zealand PDS Annual Program Statement |
19.040 |
PDS-NEWZEALAND-2023-01 |
| GPD Per Diem Only Grant Program (TIP) |
64.024 |
VA-GPD-TIP-FY2024 |
| GPD Per Diem Only Grant Program (PDO) |
64.024 |
VA-GPD-PDO-FY2024 |
Search Results 2041-2080 of 17976
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 [Next] |
